"Self-Compassion and Self-Efficacy in Parkinson's Disease: Associations With Symptoms, Function, and Quality of Life"

July 14, 2026 updated by: Nuray Alaca, Acibadem University

"Associations of Self-Compassion and Self-Efficacy With Symptom Severity, Functional Status, and Quality of Life in Individuals With Parkinson's Disease: A Cross-Sectional Study"

The aim of this study is to evaluate the associations of self-compassion and self-efficacy levels with symptom severity, functional status, and quality of life in individuals with Parkinson's disease.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population will consist of individuals diagnosed with Parkinson's disease who are classified as Hoehn and Yahr stage 1-3, aged between 40 and 85 years, and have sufficient cognitive function (MMSE ≥ 24). Participants will be recruited from patients attending the Movement Disorders Outpatient Clinic of the Neurology Department

Description

Inclusion Criteria:

  • Clinical diagnosis of Parkinson's disease
  • Hoehn and Yahr stage 1-3
  • Age 40 to 85 years
  • Mini-Mental State Examination (MMSE) score ≥24
  • Sufficient cognitive function to communicate and complete study assessments
  • Attending the Movement Disorders Outpatient Clinic, Department of Neurology
  • Able and willing to provide written informed consent

Exclusion Criteria:

  • Major depressive disorder or psychotic disorder
  • Advanced dementia
  • Uncontrolled chronic systemic disease (e.g., diabetes mellitus or hypertension)
  • Severe cardiovascular or respiratory disease
  • Additional neurological or orthopedic conditions that may affect assessment performance
  • Severe visual or hearing impairment that could interfere with study assessments
  • Inability to cooperate with the physiotherapist during study assessments

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-Compassion Scale (SCS) Total Score
Time Frame: Baseline (at the time of questionnaire completion)
Self-Compassion Scale (SCS) total score. The Self-Compassion Scale consists of 26 items scored on a 1- to 5-point Likert scale. Total scores range from 1 to 5 (calculated as the mean of all items), with higher scores indicating greater self-compassion (better outcome).
Baseline (at the time of questionnaire completion)
Self-Efficacy for Managing Chronic Disease 6-Item Scale Total Score
Time Frame: Baseline (at the time of questionnaire completion)
Self-Efficacy for Managing Chronic Disease 6-Item Scale total score. The scale consists of 6 items scored from 1 (not at all confident) to 10 (totally confident). The total score is calculated as the mean of the six items, ranging from 1 to 10, with higher scores indicating greater self-efficacy for managing chronic disease (better outcome).
Baseline (at the time of questionnaire completion)
Unified Parkinson's Disease Rating Scale (UPDRS) Total Score
Time Frame: Baseline (at the time of questionnaire completion)
Unified Parkinson's Disease Rating Scale (UPDRS) total score. The total score ranges from 0 to 199, with higher scores indicating greater Parkinson's disease severity and worse clinical status (worse outcome).
Baseline (at the time of questionnaire completion)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Timed Up and Go (TUG) Test Completion Time in Seconds
Time Frame: Baseline (at the time of questionnaire completion)
Functional mobility will be measured using the Timed Up and Go (TUG) test. The time required to stand up from a chair, walk 3 meters, turn, return, and sit down will be recorded in seconds. Longer times indicate poorer functional mobility.
Baseline (at the time of questionnaire completion)
Six-Minute Walk Test (6MWT) Distance in Meters
Time Frame: Baseline (at the time of questionnaire completion)
Functional exercise capacity will be measured using the Six-Minute Walk Test (6MWT). The total distance walked in six minutes will be recorded in meters. Greater distances indicate better functional capacity.
Baseline (at the time of questionnaire completion)
Mini-Balance Evaluation Systems Test (Mini-BESTest) Total Score
Time Frame: Baseline (at the time of questionnaire completion)
Dynamic balance will be measured using the Mini-Balance Evaluation Systems Test (Mini-BESTest), a 14-item performance-based assessment. Total scores range from 0 to 28, with higher scores indicating better balance performance.
Baseline (at the time of questionnaire completion)
Parkinson's Disease Questionnaire-39 (PDQ-39) Total Score
Time Frame: Baseline (at the time of questionnaire completion)
Quality of life will be measured using the Parkinson's Disease Questionnaire-39 (PDQ-39), a validated disease-specific instrument. Total scores range from 0 to 100, with higher scores indicating poorer quality of life.
Baseline (at the time of questionnaire completion)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Acibadem University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 30, 2026

Primary Completion (Estimated)

December 30, 2026

Study Completion (Estimated)

March 30, 2027

Study Registration Dates

First Submitted

March 18, 2026

First Submitted That Met QC Criteria

March 18, 2026

First Posted (Actual)

March 23, 2026

Study Record Updates

Last Update Posted (Actual)

July 15, 2026

Last Update Submitted That Met QC Criteria

July 14, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2026-03-130

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Clinical Trials on Self-Report Questionnaire Assessment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe